These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23075918)

  • 1. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.
    Dooley KE; Sayre P; Borland J; Purdy E; Chen S; Song I; Peppercorn A; Everts S; Piscitelli S; Flexner C
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):21-7. PubMed ID: 23075918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
    Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M
    Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.
    Le X; Guo X; Sun J; Liu L; Shen Y; Wang J; Qi T; Wang Z; Tang Y; Song W; Yin L; Zhang L; Zhang R; Chen J
    Int J Infect Dis; 2022 Mar; 116():147-150. PubMed ID: 34999246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
    Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM
    BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
    Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
    J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Cramer Y; Imperial M; Rosenkranz SL; Avihingsanon A; Arduino R; Samaneka W; Gelmanova I; Savic R; Swindells S; Dawson R; Luetkemeyer AF
    Clin Infect Dis; 2024 Oct; 79(4):983-989. PubMed ID: 38568956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.
    Song I; Mark S; Chen S; Savina P; Wajima T; Peppercorn A; Bala U; Geoffroy P; Piscitelli S
    Drug Alcohol Depend; 2013 Dec; 133(2):781-4. PubMed ID: 24018316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
    Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
    J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
    Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor.
    Singh H; Kaur M; Kakkar AK; Kumar H
    Curr Clin Pharmacol; 2016; 11(2):88-94. PubMed ID: 27157040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
    Elliot ER; Cerrone M; Challenger E; Else L; Amara A; Bisdomini E; Khoo S; Owen A; Boffito M
    J Antimicrob Chemother; 2019 Jan; 74(1):149-156. PubMed ID: 30272231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
    Elliot ER; Wang X; Singh S; Simmons B; Vera JH; Miller RF; Fitzpatrick C; Moyle G; McClure M; Boffito M
    Clin Infect Dis; 2019 Jan; 68(1):87-95. PubMed ID: 29771285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.